The Life Sciences team advised EQRx on the completion of its $500 million Series B. The financing includes participation from all Series A investors, life science specialists, world-class mutual funds and private equity funds, sovereign wealth and family offices, and market-leading payers and health systems that cover more than 20% of insured lives in the United States.
Since launching a year ago, EQRx has raised approximately $750 million to advance its mission of bringing new medicines to treat life-threatening and chronic diseases to patients and healthcare systems around the world at prices that are a fraction of the cost of today’s leading therapies.
EQRx is committed to catalyzing a market-based solution to one of society’s biggest healthcare challenges by developing important new medicines and offering them at lower prices. Through strategic partnerships with stakeholders from across the healthcare system and cutting-edge science and technology, the company aims to provide high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The Goodwin team was led by Bill Collins, Mayan Katz, and Brett Jackson with assistance from Jacob Osborne.
For additional details on the financing round, please read the coverage in Endpoints News and STAT.